Have a website account?
Log In
or
Register
for exclusive website content.
Subscribe
Advanced Search
Home
Journal Info
About
tlcr
Indexing
Editors-in-Chief
Editorial Board
Former Editorial Board
Testimonials
Peer Review Process
Supplements and Series
Advertising Policy
For Authors
Author Instructions
Online Submission
Submit Multimedia Files
Reference Style
AME Editing Service
Interviews with Outstanding Authors
For Reviewers
Guidelines for Reviewers
Online Review
Reviewers
Ethics and Policies
Journal Management (Editorial Roles)
Editorial Policies
Publication Ethics Policy
Research Ethics Policy
Human and Animal Rights
Authorship and Contributorship
Informed Consent Policy
Conflicts of Interest
Data Sharing Policy
Open Access Statement
Content Licensing
Copyright and Permission
Quality Control System
Data and Reproducibility
Policy of Screening for Plagiarism Process
Policy of Dealing with Allegations of Research Misconduct
Corrections and Retractions
Complaints and Appeals
Special Contents
Special Series (Published)
Special Series (Ongoing)
TLCR Chinese Edition
Interviews with Guest Editors
Interviews with Editorial Board Members
Archives
Online First
Article Processing Charges
News
Home
/
Archives
/
Vol 1, No 1 (March 18, 2012)
Vol 1, No 1 (March 18, 2012): Translational Lung Cancer Research
Editorial
Something in need is something indeed
Caicun Zhou, Christian Manegold, Yong Song
PDF
Pages: 1-2
Full Text
(3835)
Open Access
Research Highlight
EGFR-TKIs in EGFR-mutated lung cancer: setting the new standard for 1
st
line therapy
Jürgen Wolf
PDF
Pages: 3-4
Full Text
(3660)
Open Access
Review Articles
Advances on EGFR mutation for lung cancer
Giulio Metro, Lucio Crinò
PDF
Pages: 5-13
Full Text
(10759)
Open Access
Angiogenesis in cancer: anti-VEGF escape mechanisms
Gerald W. Prager, Marina Poettler, Matthias Unseld, Christoph C. Zielinski
PDF
Pages: 14-25
Full Text
(27853)
Open Access
Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Lothar R Pilz, Christian Manegold, Gerald Schmid-Bindert
PDF
Pages: 26-35
Full Text
(19881)
Open Access
Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review
Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song
PDF
Pages: 36-44
Full Text
(11595)
Open Access
Are three doses of SABR (stereotactic ablative radiotherapy) more effective than 30 doses of conventional radiotherapy?
Anna O. Simeonova, Katharina Fleckenstein, Hans-Jörg Wertz, Judit Boda-Heggemann, Frederik Wenz
PDF
Pages: 45-53
Full Text
(16841)
Open Access
Cetuximab in non-small-cell lung cancer
Robert Pirker, Martin Filipits
PDF
Pages: 54-60
Full Text
(9165)
Open Access
Perspectives
Chemotherapy of lung cancer: a global perspective of the role of ifosfamide
Caicun Zhou, Christian Manegold
PDF
Pages: 61-71
Full Text
(9008)
Open Access
Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy
Caicun Zhou
PDF
Pages: 72-77
Full Text
(6136)
Open Access
Functional CT imaging techniques for the assessment of angiogenesis in lung cancer
Thomas Henzler, Jingyun Shi, Hashim Jafarov, Stefan O. Schoenberg, Christian Manegold, Christian Fink, Gerald Schmid-Bindert
PDF
Pages: 78-83
Full Text
(14167)
Open Access
Updating advances on recombinant human endostatin combined with radiotherapy for non-small cell lung cancer with brain metastasis
Xiao-dong Jiang, Yun Qiao
PDF
Pages: 84-88
Full Text
(6172)
Open Access
Short Communication
Conflict-Management within clinical and administrative stakeholders in medical structures
Karl F. Brandt
PDF
Pages: 89-90
Full Text
(3889)
Open Access
Correspondence
Status quo and prospects of the translational research on lung cancer in China
Ping Zhan, Yong Song
PDF
Pages: 91-93
Full Text
(4513)
Open Access